Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Gliclazide
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Gliclazide 80mg tablets
0601021M0AAAAAA
|
Gliclazide | Gliclazide | Endocrine System | 389,504 |
|
Gliclazide 40mg tablets
0601021M0AAARAR
|
Gliclazide | Gliclazide | Endocrine System | 235,741 |
|
Gliclazide 30mg modified-release tablets
0601021M0AAAMAM
|
Gliclazide | Gliclazide | Endocrine System | 84,055 |
|
Gliclazide 60mg modified-release tablets
0601021M0AAATAT
|
Gliclazide | Gliclazide | Endocrine System | 29,158 |
|
Gliclazide 160mg tablets
0601021M0AAAVAV
|
Gliclazide | Gliclazide | Endocrine System | 9,790 |
|
Diamicron 30mg MR tablets
0601021M0BBABAM
|
Diamicron | Gliclazide | Endocrine System | 2,365 |
|
Bilxona 30mg modified-release tablets
0601021M0BNAAAM
|
Bilxona | Gliclazide | Endocrine System | 317 |
|
Zicron 40mg tablets
0601021M0BIAAAR
|
Zicron | Gliclazide | Endocrine System | 316 |
|
Gliclazide 80mg/5ml oral suspension
0601021M0AAASAS
|
Gliclazide | Gliclazide | Endocrine System | 307 |
|
Diamicron 80mg tablets
0601021M0BBAAAA
|
Diamicron | Gliclazide | Endocrine System | 182 |
|
Gliclazide 40mg/5ml oral suspension
0601021M0AAAUAU
|
Gliclazide | Gliclazide | Endocrine System | 171 |
|
Edicil MR 30mg tablets
0601021M0BGAAAM
|
Edicil | Gliclazide | Endocrine System | 102 |
|
Vamju 30mg modified-release tablets
0601021M0BMAAAM
|
Vamju | Gliclazide | Endocrine System | 80 |
|
Vamju 60mg modified-release tablets
0601021M0BMABAT
|
Vamju | Gliclazide | Endocrine System | 42 |
|
Bilxona 60mg modified-release tablets (Accord)
0601021M0BNACAT
|
Bilxona | Gliclazide | Endocrine System | 27 |
|
Zicron PR 30mg tablets
0601021M0BIABAM
|
Zicron | Gliclazide | Endocrine System | 16 |
|
Laaglyda MR 60mg tablets
0601021M0BKAAAT
|
Laaglyda M/R | Gliclazide | Endocrine System | 15 |
|
Lamzarin 30mg modified-release tablets
0601021M0BQAAAM
|
Lamzarin | Gliclazide | Endocrine System | 15 |
|
Ziclaseg 30mg modified-release tablets
0601021M0BLAAAM
|
Ziclaseg | Gliclazide | Endocrine System | 3 |
|
Glydex 160mg tablets
0601021M0BPAAAV
|
Glydex | Gliclazide | Endocrine System | 2 |
|
Dacadis MR 30mg tablets
0601021M0BHAAAM
|
Dacadis | Gliclazide | Endocrine System | 1 |
|
Lamzarin 60mg modified-release tablets
0601021M0BQABAT
|
Lamzarin | Gliclazide | Endocrine System | 1 |
|
Bilxona 60mg modified-release tablets (Actavis)
0601021M0BNABAT
|
Bilxona | Gliclazide | Endocrine System | No data available |
|
Diaglyk 80mg tablets
0601021M0BCAAAA
|
Diaglyk | Gliclazide | Endocrine System | No data available |
|
Gliclazide 100mg/5ml oral suspension
0601021M0AAALAL
|
Gliclazide | Gliclazide | Endocrine System | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.